Recent Updates
Recently added Catalysts
VALN Negative Sentiment Score: 25/100

VALNEVA ALERT: Bragar Eagel & Squire, P.C. is Investigating Valneva SE on Behalf of Valneva Stockholders and Encourages Investors to Contact the Firm

Key Takeaway: Bragar Eagel & Squire, P.C. is investigating Valneva SE on behalf of its stockholders concerning potential violations of federal securities laws. Recent events, including the CDC's investigation into hospitalizations related to Valneva's chikungunya vaccine, IXCHIQ, have led to a notable drop in the stock price. Additionally, the FDA has suspended the marketing application for IXCHIQ due to safety issues. Investors who purchased Valneva shares and suffered losses are encouraged to contact the law firm for assistance.

Market Sentiment Analysis

CONCERNS & RISKS

  • Valneva is under investigation for potentially violating federal securities laws.
  • The CDC reported hospitalizations for cardiac or neurologic events related to its chikungunya vaccine, IXCHIQ.
  • The FDA suspended the marketing application for IXCHIQ due to safety concerns.
  • Valneva's stock price has significantly declined following adverse developments.

Full Press Release Details

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Valneva (VALN) To Contact Him Directly To Discuss Their Options
If you purchased or acquired stock in Valneva and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
Click here to participate in the action.
NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) --
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Valneva SE (“Valneva” or the “Company”) (NASDAQ:VALN) on behalf of Valneva stockholders. Our investigation concerns whether Valneva has violated the federal securities laws and/or engaged in other unlawful business practices.
Investigation Details:
On February 25, 2025, the U.S. Centers for Disease Control and Prevention ("CDC") posted a notice on its website announcing that "CDC is currently investigating five hospitalizations for cardiac or neurologic events following vaccination with IXCHIQ [Valneva's chikungunya virus vaccine] among people 65 years of age and older."
Following the CDC's announcement and subsequent reporting by media outlets, Valneva's American Depositary Receipt ("ADR") price fell $1.06 per ADR, or 13.57%, over the following four trading sessions, to close at $6.75 per ADR on February 28, 2025.
Then, on August 22, 2025, the U.S. Food and Drug Administration announced that it had suspended the marketing application for IXCHIQ due to safety concerns.
On this news, Valneva's ADR price fell $2.21 per ADR, or 18.99%, to close at $9.43 per ADR on August 25, 2025.
If you purchased or otherwise acquired Valneva shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Bragar Eagel & Squire

Frequently Asked Questions

Who can investors contact regarding Valneva losses?

Investors can contact Brandon Walker or Marion Passmore at (212) 355-4648.

What triggered the investigation into Valneva?

The investigation was triggered by CDC's notice on hospitalizations linked to Valneva's vaccine.

What happened to Valneva's stock price recently?

Valneva's ADR price fell significantly after CDC and FDA announcements about safety concerns.

What is Bragar Eagel & Squire, P.C.?

It is a law firm specializing in representing investors in legal matters.

Is there a cost to contact Bragar Eagel & Squire?

No, there is no cost or obligation to contact the firm regarding your situation.

Last updated: Sep 18, 2025